These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 22948700)

  • 1. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis.
    Lopez-Olivo MA; Tayar JH; Martinez-Lopez JA; Pollono EN; Cueto JP; Gonzales-Crespo MR; Fulton S; Suarez-Almazor ME
    JAMA; 2012 Sep; 308(9):898-908. PubMed ID: 22948700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
    Maneiro JR; Souto A; Gomez-Reino JJ
    Semin Arthritis Rheum; 2017 Oct; 47(2):149-156. PubMed ID: 28284845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects of biologics: a network meta-analysis and Cochrane overview.
    Singh JA; Wells GA; Christensen R; Tanjong Ghogomu E; Maxwell L; Macdonald JK; Filippini G; Skoetz N; Francis D; Lopes LC; Guyatt GH; Schmitt J; La Mantia L; Weberschock T; Roos JF; Siebert H; Hershan S; Lunn MP; Tugwell P; Buchbinder R
    Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD008794. PubMed ID: 21328309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
    Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
    Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
    J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis.
    Desai RJ; Hansen RA; Rao JK; Wilkins TM; Harden EA; Yuen A; Jonas DE; Roubey R; Jonas B; Gartlehner G; Lux L; Donahue KE
    Ann Pharmacother; 2012 Nov; 46(11):1491-505. PubMed ID: 23092868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Cho SK; Lee J; Han M; Bae SC; Sung YK
    Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty.
    Hanson RL; Gannon MJ; Khamo N; Sodhi M; Orr AM; Stubbings J
    J Manag Care Pharm; 2013; 19(1):49-67. PubMed ID: 23383700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bronchiectasis in rheumatoid arthritis: report of four cases and a review of the literature--implications for management with biologic response modifiers.
    Lieberman-Maran L; Orzano IM; Passero MA; Lally EV
    Semin Arthritis Rheum; 2006 Jun; 35(6):379-87. PubMed ID: 16765715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
    Guyot P; Taylor PC; Christensen R; Pericleous L; Drost P; Eijgelshoven I; Bergman G; Lebmeier M
    J Rheumatol; 2012 Jun; 39(6):1198-206. PubMed ID: 22505698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
    Leombruno JP; Einarson TR; Keystone EC
    Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis.
    Venkateshan SP; Sidhu S; Malhotra S; Pandhi P
    Pharmacology; 2009; 83(1):1-9. PubMed ID: 18957873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
    Osterman MT; Sandborn WJ; Colombel JF; Robinson AM; Lau W; Huang B; Pollack PF; Thakkar RB; Lewis JD
    Gastroenterology; 2014 Apr; 146(4):941-9. PubMed ID: 24361468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies.
    Xie W; Yang X; Huang H; Gao D; Ji L; Zhang Z
    Semin Arthritis Rheum; 2020 Oct; 50(5):930-937. PubMed ID: 32906027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
    Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
    Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.